BML-210 | CAY10433 | CAS#537034-17-6 | HDAC inhibitor

MedKoo Cat#: 406718 | Name: BML-210

Description:

WARNING: This product is for research use only, not for human or veterinary use.

BML-210, also known as CAY10433, is HDAC inhibitor. BML-210 induces growth inhibition and apoptosis and regulates HDAC and DAPC complex expression levels in cervical cancer cells. BML-210 can inhibit cell growth and induce apoptosis in cervical cancer cells, what correlates with down-regulation of HDAC class I and II and changes in the DAPC expression levels.

Chemical Structure

BML-210

CAS#537034-17-6

Theoretical Analysis

MedKoo Cat#: 406718

Name: BML-210

CAS#: 537034-17-6

Chemical Formula: C20H25N3O2

Exact Mass: 339.1947

Molecular Weight: 339.44

Elemental Analysis: C, 70.77; H, 7.42; N, 12.38; O, 9.43

Price and Availability

Size	Price	Availability
25mg	USD 250.00	2 weeks
50mg	USD 450.00	2 weeks
100mg	USD 750.00	2 weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

No Data

Synonym

BML-210; BML 210; BML210; CAY10433; CAY-10433; CAY 10433.

IUPAC/Chemical Name

N-(2-aminophenyl)-N'-phenyl-octanediamide

InChi Key

RFLHBLWLFUFFDZ-UHFFFAOYSA-N

InChi Code

InChI=1S/C20H25N3O2/c21-17-12-8-9-13-18(17)23-20(25)15-7-2-1-6-14-19(24)22-16-10-4-3-5-11-16/h3-5,8-13H,1-2,6-7,14-15,21H2,(H,22,24)(H,23,25)

SMILES Code

O=C(NC1=CC=CC=C1N)CCCCCCC(NC2=CC=CC=C2)=O

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO, not in water

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Product Data

Product Data

Instruction

View handling instruction

Biological target:

BML-210 is a novel HDAC inhibitor.

In vitro activity:

BML-210 inhibited cell proliferation and growth inhibition of NB4 cells in a dose- and time-dependent manner (Figure 1A,B). 10 μM BML-210 inhibited growth of NB4 cells up to 44% and 77% at day one and two, respectively (Figure 1A). The 10 μM BML-210 treatment also caused anti-proliferative effect: the viable cell number in culture was 88% (after 24 h) and 57% (after 48 h) (Figure 1B). An even stronger effect was observed after treatment with 20 μM BML-210: 67% of viable cells were detected at 24 h point of treatment and growth inhibition up to 90% at 48 h point (Figure 1A,B). Reference: Int J Mol Sci. 2015 Aug; 16(8): 18252–18269. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4581243/

In vivo activity:

TBD

	Solvent	mg/mL	mM
Solubility
	DMSO	30.0	88.38
	DMSO:PBS (pH 7.2) (1:1)	0.5	1.47
	DMF	30.0	88.38
	Ethanol	1.0	2.95

Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 339.44 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:

1. Borutinskaitė V, Navakauskienė R. The Histone Deacetylase Inhibitor BML-210 Influences Gene and Protein Expression in Human Promyelocytic Leukemia NB4 Cells via Epigenetic Reprogramming. Int J Mol Sci. 2015 Aug 6;16(8):18252-69. doi: 10.3390/ijms160818252. PMID: 26287160; PMCID: PMC4581243. 2. Borutinskaite VV, Magnusson KE, Navakauskiene R. Histone deacetylase inhibitor BML-210 induces growth inhibition and apoptosis and regulates HDAC and DAPC complex expression levels in cervical cancer cells. Mol Biol Rep. 2012 Dec;39(12):10179-86. doi: 10.1007/s11033-012-1892-5. Epub 2012 Sep 26. PMID: 23007576.

In vitro protocol:

In vivo protocol:

TBD

1: Borutinskaitė V, Navakauskienė R. The Histone Deacetylase Inhibitor BML-210 Influences Gene and Protein Expression in Human Promyelocytic Leukemia NB4 Cells via Epigenetic Reprogramming. Int J Mol Sci. 2015 Aug 6;16(8):18252-69. doi: 10.3390/ijms160818252. PubMed PMID: 26287160; PubMed Central PMCID: PMC4581243. 2: Borutinskaite VV, Magnusson KE, Navakauskiene R. Histone deacetylase inhibitor BML-210 induces growth inhibition and apoptosis and regulates HDAC and DAPC complex expression levels in cervical cancer cells. Mol Biol Rep. 2012 Dec;39(12):10179-86. doi: 10.1007/s11033-012-1892-5. Epub 2012 Sep 26. PubMed PMID: 23007576. 3: Savickiene J, Treigyte G, Jazdauskaite A, Borutinskaite VV, Navakauskiene R. DNA methyltransferase inhibitor RG108 and histone deacetylase inhibitors cooperate to enhance NB4 cell differentiation and E-cadherin re-expression by chromatin remodelling. Cell Biol Int. 2012 Nov 1;36(11):1067-78. doi: 10.1042/CBI20110649. PubMed PMID: 22845560. 4: Savickiene J, Treigyte G, Borutinskaite VV, Navakauskiene R. Antileukemic activity of combined epigenetic agents, DNMT inhibitors zebularine and RG108 with HDAC inhibitors, against promyelocytic leukemia HL-60 cells. Cell Mol Biol Lett. 2012 Dec;17(4):501-25. Epub 2012 Jul 20. PubMed PMID: 22820861. 5: Jayathilaka N, Han A, Gaffney KJ, Dey R, Jarusiewicz JA, Noridomi K, Philips MA, Lei X, He J, Ye J, Gao T, Petasis NA, Chen L. Inhibition of the function of class IIa HDACs by blocking their interaction with MEF2. Nucleic Acids Res. 2012 Jul;40(12):5378-88. doi: 10.1093/nar/gks189. Epub 2012 Mar 6. PubMed PMID: 22396528; PubMed Central PMCID: PMC3384312. 6: Xiong P, Li YX, Tang YT, Chen HG. Proteomic analyses of Sirt1-mediated cisplatin resistance in OSCC cell line. Protein J. 2011 Oct;30(7):499-508. doi: 10.1007/s10930-011-9354-9. PubMed PMID: 21947960. 7: Savickiene J, Treigyte G, Jonusiene V, Bruzaite R, Borutinskaite VV, Navakauskiene R. Epigenetic changes by zebularine leading to enhanced differentiation of human promyelocytic leukemia NB4 and KG1 cells. Mol Cell Biochem. 2012 Jan;359(1-2):245-61. doi: 10.1007/s11010-011-1019-7. Epub 2011 Aug 13. PubMed PMID: 21842375. 8: Savickiene J, Treigyte G, Magnusson KE, Navakauskiene R. Response of retinoic acid-resistant KG1 cells to combination of retinoic acid with diverse histone deacetylase inhibitors. Ann N Y Acad Sci. 2009 Aug;1171:321-33. doi: 10.1111/j.1749-6632.2009.04718.x. PubMed PMID: 19723072. 9: Borutinskaite VV, Navakauskiene R, Magnusson KE. Retinoic acid and histone deacetylase inhibitor BML-210 inhibit proliferation of human cervical cancer HeLa cells. Ann N Y Acad Sci. 2006 Dec;1091:346-55. PubMed PMID: 17341627. 10: Savickiene J, Borutinskaite VV, Treigyte G, Magnusson KE, Navakauskiene R. The novel histone deacetylase inhibitor BML-210 exerts growth inhibitory, proapoptotic and differentiation stimulating effects on the human leukemia cell lines. Eur J Pharmacol. 2006 Nov 7;549(1-3):9-18. Epub 2006 Aug 15. PubMed PMID: 16978604. 11: Herman D, Jenssen K, Burnett R, Soragni E, Perlman SL, Gottesfeld JM. Histone deacetylase inhibitors reverse gene silencing in Friedreich's ataxia. Nat Chem Biol. 2006 Oct;2(10):551-8. Epub 2006 Aug 20. Erratum in: Nat Chem Biol. 2007 Jul;3(7):432. PubMed PMID: 16921367.

View History

Abscisic acid

MedKoo CAT#: 525980

CAS#: 21293-29-8